Akari Therapeutics, Plc Preferred Shares: Authorized and Outstanding
The company's filed XBRL preferred stock facts (us-gaap Preferred*), one row per period end, newest first. Values are as filed.
- 2024-06-30: Preferred Stock, Value, Issued $0.00; Preferred Stock, Par or Stated Value Per Share $0.00; Preferred Stock, Shares Authorized 10.00M shares.
- 2023-12-31: Preferred Stock, Value, Issued $0.00; Preferred Stock, Par or Stated Value Per Share $0.00; Preferred Stock, Shares Authorized 10.00M shares; Preferred Stock, Shares Issued 0.00 shares.
- 2022-12-31: Preferred Stock, Value, Issued $0.00; Preferred Stock, Par or Stated Value Per Share $0.00; Preferred Stock, Shares Authorized 10.00M shares; Preferred Stock, Shares Issued 0.00 shares.
| Period end | Preferred Stock, Value, Issued | Preferred Stock, Par or Stated Value Per Share | Preferred Stock, Shares Authorized | Preferred Stock, Shares Issued | Preferred Stock, Shares Outstanding |
|---|---|---|---|---|---|
| 2024-06-30 | $0.00 8-K · filed 2024-09-06 | $0.00 8-K · filed 2024-09-06 | 10.00M shares 8-K · filed 2024-09-06 | 0.00 shares 8-K · filed 2024-09-06 | |
| 2023-12-31 | $0.00 8-K · filed 2024-09-06 | $0.00 8-K · filed 2024-09-06 | 10.00M shares 8-K · filed 2024-09-06 | 0.00 shares 8-K · filed 2024-09-06 | 0.00 shares 8-K · filed 2024-09-06 |
| 2022-12-31 | $0.00 8-K · filed 2024-09-06 | $0.00 8-K · filed 2024-09-06 | 10.00M shares 8-K · filed 2024-09-06 | 0.00 shares 8-K · filed 2024-09-06 | 0.00 shares 8-K · filed 2024-09-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |